Kamada's shares saw a decline following the announcement that the company has halted its Phase 3 study of an inhaled Alpha-1 Antitrypsin (AAT) therapy. The decision to stop the clinical trial is a significant setback for the development of this particular AAT treatment.

KMDA

<p>Kamada 的股票在公司宣布暂停其吸入型α-1 抗胰蛋白酶（AAT）治疗的第三阶段研究后出现下跌。停止临床试验的决定对该 AAT 治疗的开发是一个重大挫折</p>

由于公司暂停吸入式 AAT 疗法的第三阶段研究，Kamada 股价下跌